Abstract
Presentation Description :
Belinostat is a histone deacetylase inhibitor. We present our preclinical work developing belinostat, via the intra-arterial and intravitreal routes, for the treatment of retinoblastoma. Pharmacokinetic and dose level data are presented, as well as toxicity experiments and maximum tolerable dose calculations. In addition, we demonstrate the efficacy of both intra-arterial and intravitreal belinostat for the treatment of intraocular retinoblastoma in a rabbit xenograft model. Comparinsons to melphalan are presented in the same model systems, demonstarting comparable efficacy of belinostat, but without the retinal toxicity seen with melphalan.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.